recombinant H5N1 influenza hemagglutinin vaccine

A **recombinant H5N1 influenza hemagglutinin vaccine** is a vaccine developed using recombinant DNA technology to express the hemagglutinin (HA) surface glycoprotein of the highly pathogenic avian influenza A H5N1 virus. Unlike traditional egg-based or cell-based inactivated vaccines, this vaccine platform uses recombinant protein expression systems (such as insect cells or other host cells) to produce the HA antigen. The vaccine is designed to induce neutralizing antibody and cell-mediated immune responses against the H5N1 virus, providing protection against avian influenza (bird flu). Some formulations include adjuvants (such as oil-in-water emulsions like GLA-SE, alum, or others) to enhance immunogenicity and allow dose sparing. Recombinant hemagglutinin vaccines offer faster, more scalable production compared to traditional vaccine manufacturing[5]. Several versions have entered clinical development (e.g., Panblok by Protein Sciences, HAI-05 by Fraunhofer, Vax161 by VaxInnate, and investigational VLP/HA candidates by Novavax and Medicago)[5].

Brand names

PanblokHAI-05HAI05HAI 05Vax161Vax-161Vax 161

Other names

recombinant H5N1 influenza vaccinerecombinant hemagglutinin H5N1 vaccinerHA H5N1 vaccine